Once-Daily Sparfloxacin Versus High-Dosage Amoxicillin in the Treatment of Community-Acquired, Suspected Pneumococcal Pneumonia in Adults
The objective of this randomized, double-blind, multicenter study of 329 adult patients requiring hospitalization was to compare the safety and efficacy of sparfloxacin at a dosage of 200 mg once daily (following a 400-mg loading dose on day 1) with those of amoxicillin given as a 1-g oral dose thre...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 1998-06, Vol.26 (6), p.1312-1320 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1320 |
|---|---|
| container_issue | 6 |
| container_start_page | 1312 |
| container_title | Clinical infectious diseases |
| container_volume | 26 |
| creator | Aubier, M. Aubie Verster, R. Regamey, C. Geslin, P. Vercken, J.-B. |
| description | The objective of this randomized, double-blind, multicenter study of 329 adult patients requiring hospitalization was to compare the safety and efficacy of sparfloxacin at a dosage of 200 mg once daily (following a 400-mg loading dose on day 1) with those of amoxicillin given as a 1-g oral dose three times daily for treatment of community-acquired pneumonia suspected to be due to Streptococcus pneumoniae. Success of treatment was determined by a combination of clinical assessment and chest radiography. Pneumococcal pneumonia was the confirmed diagnosis for 177 patients (54%). Overall rates of success among evaluable patients were equivalent between drugs, both at the end of treatment (sparfloxacin, 92%; amoxicillin, 87%) and at follow-up (sparfloxacin, 89%; amoxicillin, 84%). Sparfloxacin was well-tolerated and produced fewer gastrointestinal effects than amoxicillin. In conclusion, sparfloxacin is a safe and effective alternative to high-dose amoxicillin for the treatment of suspected pneumococcal community-acquired pneumonia. |
| doi_str_mv | 10.1086/516366 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_17270962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4460380</jstor_id><sourcerecordid>4460380</sourcerecordid><originalsourceid>FETCH-LOGICAL-c343t-46c19ed45a3fb79a613074c0f4ecfbdd89b940759fd1052f2a55e271be9c12f13</originalsourceid><addsrcrecordid>eNpFkM9KJDEQh5tlF9ZV9wk85OTJaNL5130cxt0dQVQYFdlLyKQrGk13xiQNM4-wb70tIwoFVcX3UVC_qvpJySkljTwTVDIpv1R7VDCFpWjp12kmosG8Yc336kfOz4RQ2hCxV_27Hizgc-PDFi3XJrkQN8b6Ad1DymNGC__4hM9jNo-AZn3ceOtDmPBU5QnQbQJTehgKig7NY9-Pgy9bPLOvo0_QnaDlmNdgC3ToZoCxjzZaa8L7MnjzdmjWjaHkg-qbMyHD4Xvfr-5-_7qdL_Dl9Z-L-ewSW8ZZwVxa2kLHhWFupVojKSOKW-I4WLfquqZdtZwo0bpu-rl2tRECakVX0FpaO8r2q-Pd3XWKryPkonufLYRgBohj1lTVirSy_hRtijkncHqdfG_SVlOi35LWu6Qn8WgnPucS04fFuSSsIRPGO-xzgc0HNulFS8WU0IuHv3pB75dXD0uib9h_vaWKtA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17270962</pqid></control><display><type>article</type><title>Once-Daily Sparfloxacin Versus High-Dosage Amoxicillin in the Treatment of Community-Acquired, Suspected Pneumococcal Pneumonia in Adults</title><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Aubier, M. Aubie ; Verster, R. ; Regamey, C. ; Geslin, P. ; Vercken, J.-B.</creator><creatorcontrib>Aubier, M. Aubie ; Verster, R. ; Regamey, C. ; Geslin, P. ; Vercken, J.-B.</creatorcontrib><description>The objective of this randomized, double-blind, multicenter study of 329 adult patients requiring hospitalization was to compare the safety and efficacy of sparfloxacin at a dosage of 200 mg once daily (following a 400-mg loading dose on day 1) with those of amoxicillin given as a 1-g oral dose three times daily for treatment of community-acquired pneumonia suspected to be due to Streptococcus pneumoniae. Success of treatment was determined by a combination of clinical assessment and chest radiography. Pneumococcal pneumonia was the confirmed diagnosis for 177 patients (54%). Overall rates of success among evaluable patients were equivalent between drugs, both at the end of treatment (sparfloxacin, 92%; amoxicillin, 87%) and at follow-up (sparfloxacin, 89%; amoxicillin, 84%). Sparfloxacin was well-tolerated and produced fewer gastrointestinal effects than amoxicillin. In conclusion, sparfloxacin is a safe and effective alternative to high-dose amoxicillin for the treatment of suspected pneumococcal community-acquired pneumonia.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/516366</identifier><language>eng</language><publisher>The University of Chicago Press</publisher><subject>Antibiotics ; Blood ; Clinical Articles ; Dosage ; Etiology ; Infections ; Pathogens ; Penicillin ; Pneumococcal pneumonia ; Pneumonia ; Sputum ; Streptococcus pneumoniae</subject><ispartof>Clinical infectious diseases, 1998-06, Vol.26 (6), p.1312-1320</ispartof><rights>Copyright 1998 The Infectious Diseases Society of America</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c343t-46c19ed45a3fb79a613074c0f4ecfbdd89b940759fd1052f2a55e271be9c12f13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4460380$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4460380$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27923,27924,58016,58249</link.rule.ids></links><search><creatorcontrib>Aubier, M. Aubie</creatorcontrib><creatorcontrib>Verster, R.</creatorcontrib><creatorcontrib>Regamey, C.</creatorcontrib><creatorcontrib>Geslin, P.</creatorcontrib><creatorcontrib>Vercken, J.-B.</creatorcontrib><title>Once-Daily Sparfloxacin Versus High-Dosage Amoxicillin in the Treatment of Community-Acquired, Suspected Pneumococcal Pneumonia in Adults</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>The objective of this randomized, double-blind, multicenter study of 329 adult patients requiring hospitalization was to compare the safety and efficacy of sparfloxacin at a dosage of 200 mg once daily (following a 400-mg loading dose on day 1) with those of amoxicillin given as a 1-g oral dose three times daily for treatment of community-acquired pneumonia suspected to be due to Streptococcus pneumoniae. Success of treatment was determined by a combination of clinical assessment and chest radiography. Pneumococcal pneumonia was the confirmed diagnosis for 177 patients (54%). Overall rates of success among evaluable patients were equivalent between drugs, both at the end of treatment (sparfloxacin, 92%; amoxicillin, 87%) and at follow-up (sparfloxacin, 89%; amoxicillin, 84%). Sparfloxacin was well-tolerated and produced fewer gastrointestinal effects than amoxicillin. In conclusion, sparfloxacin is a safe and effective alternative to high-dose amoxicillin for the treatment of suspected pneumococcal community-acquired pneumonia.</description><subject>Antibiotics</subject><subject>Blood</subject><subject>Clinical Articles</subject><subject>Dosage</subject><subject>Etiology</subject><subject>Infections</subject><subject>Pathogens</subject><subject>Penicillin</subject><subject>Pneumococcal pneumonia</subject><subject>Pneumonia</subject><subject>Sputum</subject><subject>Streptococcus pneumoniae</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNpFkM9KJDEQh5tlF9ZV9wk85OTJaNL5130cxt0dQVQYFdlLyKQrGk13xiQNM4-wb70tIwoFVcX3UVC_qvpJySkljTwTVDIpv1R7VDCFpWjp12kmosG8Yc336kfOz4RQ2hCxV_27Hizgc-PDFi3XJrkQN8b6Ad1DymNGC__4hM9jNo-AZn3ceOtDmPBU5QnQbQJTehgKig7NY9-Pgy9bPLOvo0_QnaDlmNdgC3ToZoCxjzZaa8L7MnjzdmjWjaHkg-qbMyHD4Xvfr-5-_7qdL_Dl9Z-L-ewSW8ZZwVxa2kLHhWFupVojKSOKW-I4WLfquqZdtZwo0bpu-rl2tRECakVX0FpaO8r2q-Pd3XWKryPkonufLYRgBohj1lTVirSy_hRtijkncHqdfG_SVlOi35LWu6Qn8WgnPucS04fFuSSsIRPGO-xzgc0HNulFS8WU0IuHv3pB75dXD0uib9h_vaWKtA</recordid><startdate>19980601</startdate><enddate>19980601</enddate><creator>Aubier, M. Aubie</creator><creator>Verster, R.</creator><creator>Regamey, C.</creator><creator>Geslin, P.</creator><creator>Vercken, J.-B.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>19980601</creationdate><title>Once-Daily Sparfloxacin Versus High-Dosage Amoxicillin in the Treatment of Community-Acquired, Suspected Pneumococcal Pneumonia in Adults</title><author>Aubier, M. Aubie ; Verster, R. ; Regamey, C. ; Geslin, P. ; Vercken, J.-B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c343t-46c19ed45a3fb79a613074c0f4ecfbdd89b940759fd1052f2a55e271be9c12f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Antibiotics</topic><topic>Blood</topic><topic>Clinical Articles</topic><topic>Dosage</topic><topic>Etiology</topic><topic>Infections</topic><topic>Pathogens</topic><topic>Penicillin</topic><topic>Pneumococcal pneumonia</topic><topic>Pneumonia</topic><topic>Sputum</topic><topic>Streptococcus pneumoniae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aubier, M. Aubie</creatorcontrib><creatorcontrib>Verster, R.</creatorcontrib><creatorcontrib>Regamey, C.</creatorcontrib><creatorcontrib>Geslin, P.</creatorcontrib><creatorcontrib>Vercken, J.-B.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aubier, M. Aubie</au><au>Verster, R.</au><au>Regamey, C.</au><au>Geslin, P.</au><au>Vercken, J.-B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Once-Daily Sparfloxacin Versus High-Dosage Amoxicillin in the Treatment of Community-Acquired, Suspected Pneumococcal Pneumonia in Adults</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>1998-06-01</date><risdate>1998</risdate><volume>26</volume><issue>6</issue><spage>1312</spage><epage>1320</epage><pages>1312-1320</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>The objective of this randomized, double-blind, multicenter study of 329 adult patients requiring hospitalization was to compare the safety and efficacy of sparfloxacin at a dosage of 200 mg once daily (following a 400-mg loading dose on day 1) with those of amoxicillin given as a 1-g oral dose three times daily for treatment of community-acquired pneumonia suspected to be due to Streptococcus pneumoniae. Success of treatment was determined by a combination of clinical assessment and chest radiography. Pneumococcal pneumonia was the confirmed diagnosis for 177 patients (54%). Overall rates of success among evaluable patients were equivalent between drugs, both at the end of treatment (sparfloxacin, 92%; amoxicillin, 87%) and at follow-up (sparfloxacin, 89%; amoxicillin, 84%). Sparfloxacin was well-tolerated and produced fewer gastrointestinal effects than amoxicillin. In conclusion, sparfloxacin is a safe and effective alternative to high-dose amoxicillin for the treatment of suspected pneumococcal community-acquired pneumonia.</abstract><pub>The University of Chicago Press</pub><doi>10.1086/516366</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 1998-06, Vol.26 (6), p.1312-1320 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17270962 |
| source | JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
| subjects | Antibiotics Blood Clinical Articles Dosage Etiology Infections Pathogens Penicillin Pneumococcal pneumonia Pneumonia Sputum Streptococcus pneumoniae |
| title | Once-Daily Sparfloxacin Versus High-Dosage Amoxicillin in the Treatment of Community-Acquired, Suspected Pneumococcal Pneumonia in Adults |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T03%3A45%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Once-Daily%20Sparfloxacin%20Versus%20High-Dosage%20Amoxicillin%20in%20the%20Treatment%20of%20Community-Acquired,%20Suspected%20Pneumococcal%20Pneumonia%20in%20Adults&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Aubier,%20M.%20Aubie&rft.date=1998-06-01&rft.volume=26&rft.issue=6&rft.spage=1312&rft.epage=1320&rft.pages=1312-1320&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1086/516366&rft_dat=%3Cjstor_proqu%3E4460380%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17270962&rft_id=info:pmid/&rft_jstor_id=4460380&rfr_iscdi=true |